Rakovina Therapeutics Inc (RKV : TSX-V)
Common Stock
$0.22
CAD
-0.01 (-2.22%)
Last updated: 2026-09-02
Get RKV alerts:
RKV
Rakovina Therapeutics Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+4.76%
1 Month
+69.23%
YTD
+120.00%
Key Statistics
Market Cap
$5.37M
52W High
$0.44
52W Low
$0.09
P/E Ratio
-
50 Day MA
$0.14
200 Day MA
$0.13
Beta
-0.22
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/2/2026 | $0.23 | $0.23 | $0.22 | $0.22 | $0.22 | 27,000 |
| 9/1/2026 | $0.23 | $0.23 | $0.20 | $0.23 | $0.23 | 18,100 |
| 8/31/2026 | $0.23 | $0.23 | $0.17 | $0.17 | $0.17 | 12,613 |
| 8/28/2026 | $0.22 | $0.22 | $0.22 | $0.22 | $0.22 | 500 |
| 8/26/2026 | $0.18 | $0.23 | $0.18 | $0.21 | $0.21 | 74,001 |
| 8/25/2026 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | 32,000 |
| 8/24/2026 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | 2,946 |
| 8/21/2026 | $0.15 | $0.20 | $0.15 | $0.19 | $0.19 | 3,000 |
| 8/19/2026 | $0.20 | $0.20 | $0.18 | $0.18 | $0.18 | 7,100 |
| 8/18/2026 | $0.18 | $0.19 | $0.18 | $0.19 | $0.19 | 66,500 |
Analyst Price Targets
Based on analyst covering RKV
Wall Street analysts forecast RKV stock price to rise 13.6% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.25
+13.6% Upside
Current Price
C$0.22
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RKV's historical volatility
30-Day Vol
167.1%
Annualized
90-Day Vol
138.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.26
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.23 | C$0.13 – C$0.42 |
| 60 trading days | C$0.25 | C$0.11 – C$0.56 |
| 90 trading days | C$0.26 | C$0.10 – C$0.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATR"mTOR inhibitor drug candidates. It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-7.11M
- Profit Margin
- 0.00%
- ROE (TTM)
- -891.37%
- EPS (Diluted)
- -0.41
- Book Value
- -0.02
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About RKV
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.
RKV.V news timeline
4 articles covering RKV.V, most recent first
Latest